고위험도 전립선암 환자의 치료 편집하기 (부분)

== 참고문헌 ==
1. Yossepowitch O, Eggener SE, Bianco FJ, Jr., Carver BS, Serio A, Scardino PT, et al, Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. The Journal of Urology 2007;178(2):493-9; discussion 9. 

2. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. The Journal of Urology 2004;172(6 Pt 1):2252-5. 

3. Zwergel U, Lehmann J, Wullich B, Schreier U, Remberger K, Zwergel T, et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. The Journal of Urology 2004:171(3):1128-31. 

4. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014;32(35):3939-47. 

5. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. The Lancet Oncology 2006;7(6):472-9. 

6. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. The Journal of Urology 2007;178(3 Pt 1):864-70; discussion 70-1. 

7. Schroder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, Debois M, et al. Early versus delayed endocrine treatment of PN1-3 MO prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study. The Journal of Urology 2004;172(3):923-7. 

8. Kirk D. Timing and choice of androgen ablation. Prostate cancer and Prostatic Diseases 2004:7(3):217-22. 

9. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. The Cochrane Database of Systematic Reviews 2002(1):Cd003506. 

10. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer. The New England Journal of Medicine 1999:341(24):1781-8. 

11. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology 2007:25(12):1596 605. 

12. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. Journal of Clinical Oncology 2009;27(1):100-5. 

13. Park S, Kim SC, Kim W, Song C, Ahn H. Impact of adjuvant androgen-deprivation therapy on disease prog ression in patients with node-positive prostate cancer. Korean Journal of Urology 2011;52(11):741-5. 

14. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. The Journal of Urology 1999:161(4):1223-7; discussion 7-8. 

15. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. The Cochrane Database of Systematic Reviews 2006(4):Cd006019. 

16. Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. European Urology 2017.